Leukemia News and Research

RSS
Leukemia (Leukaemia) is a cancer of the blood cells. It is the most common type of blood cancer and affects 10 times as many adults as children. Most people diagnosed with leukemia are over 50 years old. No one knows why some people develop leukemia and others do not. However, scientists have identified some risk factors for the disease. Most people who have known risk factors do not get leukemia, while many who do get the disease have none of these risk factors. During the early stages of leukemia, there may be no symptoms. Many of the symptoms of leukemia don't become apparent until a large number of normal blood cells are crowded out by leukemia cells.
Chemotherapy-free combination treatment outperforms traditional regimens in patients with Ph+ ALL

Chemotherapy-free combination treatment outperforms traditional regimens in patients with Ph+ ALL

Evidence grows for pirtobrutinib as a safer and effective alternative for CLL and SLL

Evidence grows for pirtobrutinib as a safer and effective alternative for CLL and SLL

Aza-ven shows superior outcomes compared to induction chemotherapy in AML patients

Aza-ven shows superior outcomes compared to induction chemotherapy in AML patients

Fixed-duration therapy works as effectively as continuous treatment for chronic lymphocytic leukemia

Fixed-duration therapy works as effectively as continuous treatment for chronic lymphocytic leukemia

Chemotherapy-based conditioning matches outcomes of total body irradiation for MRD-negative B-ALL

Chemotherapy-based conditioning matches outcomes of total body irradiation for MRD-negative B-ALL

Many families of children with leukemia face significant financial hardship during treatment

Many families of children with leukemia face significant financial hardship during treatment

Black patients with AML experience earlier onset and poorer outcomes

Black patients with AML experience earlier onset and poorer outcomes

New investment aims to accelerate treatments for low-grade brain tumors

New investment aims to accelerate treatments for low-grade brain tumors

A new generation of AML treatments brings hope for better survival

A new generation of AML treatments brings hope for better survival

New consortium aims to fast-track breakthroughs against follicular lymphoma

New consortium aims to fast-track breakthroughs against follicular lymphoma

Study demonstrates a safer strategy for allogeneic stem cell transplants

Study demonstrates a safer strategy for allogeneic stem cell transplants

Breakthrough platform reveals the choreography of mammalian transcription

Breakthrough platform reveals the choreography of mammalian transcription

Breakthrough immunotherapy approved for treatment of adults with aggressive blood cancer

Breakthrough immunotherapy approved for treatment of adults with aggressive blood cancer

New medication offers potential treatment for patients with deadliest form of blood cancer

New medication offers potential treatment for patients with deadliest form of blood cancer

Young donor age proves critical for survival after stem cell transplantation

Young donor age proves critical for survival after stem cell transplantation

CAR T cell therapy could be a highly effective tool against atherosclerosis

CAR T cell therapy could be a highly effective tool against atherosclerosis

Generative AI tool enhances accuracy in detecting abnormal blood cells

Generative AI tool enhances accuracy in detecting abnormal blood cells

New transplant approach resets the immune system to stop Type 1 diabetes

New transplant approach resets the immune system to stop Type 1 diabetes

Researchers identify key differences between two subtypes of chronic lymphocytic leukemia

Researchers identify key differences between two subtypes of chronic lymphocytic leukemia

Mapping the health hazards of fossil fuel infrastructure

Mapping the health hazards of fossil fuel infrastructure

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.